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~orn~titj~n between Giprotein and the s~theti~ peptide, GSA 379-394, derived ffom the ~r~xyl-te~inal region of the ~~sub~~t, led to com- 
plete inhibition of receptor-mediated a enylate cyclase activation in turkey erytbrocyte membranes. Related peptides corresponding to the homo- 
logous carboxyl-terminal region of et-, q- or a,-subunits did not interfere with /&receptar-G, coupling. The direct coupling between G, and adenyl- 
ate cyclase was not influenced by any of these peptides. These results emphasize the important role of the carboxyl-terminus of G-protein cl-subunits 
for the specific recognition of their corresponding receptors and for signal transduction. 
A~~~~tor~ _&; C&-protein; Coupring domain; Synthetic pep%& Anti-peptide antibody 
1, INTRODUCTION 
G*proteins transfer information from cell surface 
receptors to effector enzymes located on the 
cytoplasmic face of plasma membranes. The 
stimulatory G-protein (G,) mediates the transfer of the 
Badrenergic signal to the target enzyme adenylate 
cyclase (C). A better comprehension of the mechanisms 
of signal tr~sdu~tion may be obtains by identifica- 
tion of the mutual eontact sites of each of the com- 
ponents of the adenylate cyclase complex. Wsing the 
site-specific peptide competition strategy, we have sue- 
cessfully characterized several receptor contact do- 
mains interacting with G, [l]. In this contribution, we 
describe the extension of our studies to localize the 
region of the Gs-protein ru-subunit involved in coupling 
to the ,&adrenoceptor . 
The signal transducing G-proteins are composed of 3 
distinct subunits +xtul p and r). While the o-subunit is 
capable of binding and hydrolyzing guanine 
nu~I~tides and activates the effector enzyme dire&y, 
the role of the .&r complex is sail1 a matter of specula- 
tion. By means of cDNA cloning techniques, a large 
number of GTP-binding ar-chains have been identified 
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A bbrevirraians: Gs-protein, guanfne nucleotide-biding protein 
mediating stimulation of adenylate cyclase; LY$, a, and tyirI cu-subunits 
of corresponding G-proteins; C, adenyiate cycfase; GTF$S, 
guanosine- ’ -o-f3-thiotriptrospbate~ TPA, trj~uo~aceti~ acid 
to date [2]. Most tissues contain two major forms of cyS- 
subunits ranging from 44.5 to 46 kDa. The human tyS 
is ~~rn~osed of 4 splice variants which arise from alter- 
native splicing of a single precursor mRNA [3]. Turkey 
erythrocyte as, which has not yet been cloned, consists 
of only one a-subunit form, shown by SDS-PAGE to 
have an apparent && of 45 kDa [4]. While the extent of 
sequence identity between the different m~rn~ian cy- 
subunits can be as low as 37%, the homolo~ among 
different mammalian fan is nearIy 100% f5]. The regions 
of diverse G-protein ru-subunits involved in the binding 
of nucleotides and in coupling to receptor or effector 
protein are currently under investigation. Besides a 
common GTP-binding domain, there are some regions 
wbi~h have been proposed to be essenti~ for an interac- 
tion of a-subunits with other components of signal 
transduction chains [6]. There are several lines of 
evidence that the carboxyl terminus of LY~ represents at 
least one part of the contact domains interacting with 
the &receptor. The most informative evidence came 
from studies with the ~~C~rnot~t of S@ mouse lym- 
phoma ceIIs which is characterized by a lack of 
receptor-mediated stimulative of adenylate cyclase. 
The uncoupling was demonstrated to result from a 
single arginine-to-proline substitution in the position 
-6 from the C-terminus [?,8]. supposing evidence was 
obt~ned from studies with the rhodopsin-tr~sducin 
system where C-terminal peptides of a*1 and correspon- 
ding antibodies were able to attenuate the receptor-G- 
protein coupling efficiency 19, lo]. Recent structural 
and functional studies on G,-interaction to receptor 
and effector have been performed exclusively by means 
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of antibodies raised against the carboxyl-terminal 
decapeptide [18]. In this case, the interpretation of the 
functional results was ambiguous. Although there was 
clear evidence for the participation of cys C-terminus in 
receptor coupling, an involvement of the same region in 
effector coupling could not be excluded. Binding of an- 
tibodies to the target regions might cause unspecific ef- 
fects like steric hindrance, or change the 
conformations transition states required for effective 
coupling. In the present study, we provide evidence that 
direct competition using synthetic peptides derived 
from the C-terminal part of different G-protein cy- 
subunits, when compared to the antibody approach, 
was more selective in differentiation between a-subunit 
coupling to receptor and to effector protein. Our 
results demonstrate that the extreme C-terminal part of 
the Gs-protein cu-subunit is involved preferentially in 
coupling to the P-receptor. 
2. MATERIALS AND METHODS 
t-Boc-amino acids were from Novabiochem, TFA was from Kali- 
Chemie. Other reagents for peptide synthesis were from Applied 
Biosystems. [+“P]ATP (600 Ci/mmol) was from New England 
Nuclear. MBS and EDCI were from Sigma. AuroProbe BL plus 
GAR immunogold reagent and IntenSE BL silver enhancement 
system were from Janssen (Belgium). All other chemicals and 
biochemicals were of the highest grade commercially available and 
were obtained from the same sources as in [l]. 
2.1. Peptide synthesis 
Peptides were synthesized by the solid-phase Merrifield method on 
an Applied Biosystems 430A synthesizer. Amino acids were coupled 
in DMF as s~met~cal anhydrides with the exception of Gin and Asn 
which were coupled as HOBt-esters. Deprotection. cleavage and 
purification were carried out as described earlier [l]. 
2.2. Antipeptide antibodies 
Peptide-specific antibodies were produced by immunization with 
Cys-containing peptides coupled to keyhole limpet hemocyanin 
(KLH) [ll]. 10 mg of KLH in 0.5 ml 10 mM phosphate buffer, pH 
7.4, were reacted by slow addition of 2 mg ~-maleimidobenzoyl N- 
succinimide ester (MBS) in 0.1 ml dimethylformamide for I h. The 
activated carrier was passed through a 1 x 5 cm Sephadex G-25 col- 
umn in 50 mM phosphate buffer, pH 7, and added to 10 mg of the 
reduced peptide. After 3 h, 10 mg 
I-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) were added, 
the mixture was readjusted to pH 7 and kept for 1 h before dialysis 
against phosphate-buffers saline at pH 7.2. Alternatively, peptides 
containing no Cys residues were activated first by reacting with 1 mg 
EDCI per mg peptide in a minimal volume of water (pH ~3) prior 
to conjugation to KLH at pH 9 [12]. 
New Zealand White rabbits were immunized by multisited in- 
tradermal or subcutaneous injections of a total of 300-5OOpg 
peptide-KLH conjugate in complete Freund’s adjuvant. Boost injec- 
tions were applied after 3 and 5 weeks (and every 4 weeks thereafter) 
with incomplete Freund’s adjuvant. Blood was obtained before im- 
munization and 10 days after the boost injections. Serum was stored 
frozen at -2O’C. 
For ELISA, microtiter plates were coated with 100 ng of peptide 
in 50 ~1 10 mM phosphate buffer per well and baked at 40°C over- 
night [13]. Washing and blocking followed standard procedures. 
Serial dilutions of peptide antisera were applied. The titer was 
calculated from the 50% point of the dilution curve. 
2.3. Immunoblotting 
Samples (50-100 ng G-protein or 1OOpg membrane protein) were 
subjected to SDS-PAGE on 11% gels. Electrophoretic transfer of 
proteins to nitrocellulose membranes was carried out in 25 mM Tris, 
I92 mM glyeine, pH 8.3, at constant current (0.15 A) for 15 h at 
4°C. Nitrocellulose sheets were blocked with 5% dried skimmed-milk 
in 10 mM Tris, 150 mM NaCl, pH 7.3, and incubated for 2 h with 
1: 400 dilutions of antisera, followed by 1: 100 dilution of AuroProbe 
BL plus goat anti-rabbit IgG for 2 h, washed with 0.1% bovine serum 
albumin in phosphate-buffered saline, pH 7.4, and further silver- 
enhanced [14]. To test the ability of peptides to block the antisera 
reactivity, the antisera (I : 400 dilution) were preincubated with in- 
creasing amounts of peptides for 1 h at 0°C. 
2.4. Membrane preparations and purification of Gs/Gi-proteins 
Purified turkey erythrocyte membranes were prepared according to 
Puchwein et al. [15]. G,- and Gi-proteins from turkey erythrocytes 
were purified according to Hanski et al. [4]. Deactivation of G, was 
carried out as described by Feder et al. 1161. 
2.5. Adenylate cyclase assay 
Adenylate cyclase activity in intact membranes was measured at 
32’C for 20 min in a final volume of 150~1 containing 20 mM 
Hepes, pH 7.8, 45 mM NaCl, 3 mM MgClz, 5 mM theophylline, 
10 mM creatine phosphate, 0.2 mg/ml creatine kinase, 0.5 mM ATP 
and l-3 pCi [LU-“P]ATP per assay. [32P]cAMP formed was isolated 
and determined according to Salomon et al. [17]. 
2.6. Activation of G, in turkey erythrocyte membranes 
The competition experiments in the presence or absence of syn- 
thetic peptides or specific antibodies were carried out exclusively with 
intact turkey erythrocyte membranes. The final peptide concentra- 
tions or antisera dilutions were as indicated in the legends to the 
figures. Hormone-induced activation of G, was achieved with 10-s M 
L-isoproterenol, 5 x lo-’ M GTPrS and 0.5 mM MgClz at 37°C for 
5 min. To measure the fluoride-mediated cyclase activity, the mem- 
branes were preincubated with 30,uM AlClr, 6 mM MgCl2 and 
10 mM NaF for 40 min at 30°C. The synthetic peptides were prein- 
cubated with membranes for 60 min at 4°C. while the incubation 
with antibodies was carried out overnight at 4°C with gentle shaking. 
3. RESULTS AND DISCUSSION 
In a previous paper [l], we reported the mapping of 
some interaction sites between &adrenoceptor and Gs 
in turkey erythrocyte membranes using the technique of 
site-specific peptide competition. In the present study 
we have focussed on the carboxyl-terminal region of ays 
and describe the ability of (;ys peptide GSA 379-394 to 
attenuate ,&adrenergic signal transduction. In addition 
we have tested C-terminal peptides from transducin cy, 
c+- and ail-subunit for possible interference in the same 
test system. Amino acid compositions of C-terminal 
peptides and their sequence alignment are shown in 
table 1. As shown in fig. 1, the addition of the peptide 
Table 1 
Comparison of amino acid sequences of C-terminal parts of different 
G-protein e-subunits 
(YI (379-394) CRDI I QRMHLRQYELL 
Cyil (339-354) VTDVI I KNNLKDCGLF 
at(r) (335-350) VTDI I I KENLKDCGLF 
a, (339-354) VTDI I I ANNLRGCGLY 
The sequences were taken from Lochrie and Simon 1191 
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Fig. 1 I Effects of synthetic peptides an &receptor-mediated cyclase 
activation in turkey erythrocyte membranes. Before activation, the 
membranes were incubated in the presence of peptides for 60 min at 
4YI. Subsequently, the hormone-induced Gs-activation was carried 
out for 5 min at 37°C with 5 x 10v7 M GTPyS and lO_’ M L- 
isoproterenof or W5 M L-propranolof. The antagonist-induced 
activation, which was about 5% of total activity, has been 
subtracted. The peptide GTA 340-350 (xf represents the C-terminus 
of transducin a, GUA 343-354 (A) represents the C-terminus of tu,, 
GSA i92-206 (e) and GSA 379-394 (0) are derived from es, and T 
138-159 represents the second intracellular loop of the 
fit-adrenoceptor. 
GSA 379-394, corresponding to the extreme carboxyl- 
terminal region, to the intact turkey erythrocyte mem- 
branes caused strong concentration-dependent inbibi- 
tion of hormone-induced cyclase activation with I& 
values of 12pM. Complete uncoupling was observed 
above 100 PM. The c~boxyl-terrni~~ part of 
transducin cr-subunit (a;, has been shown to be involv- 
ed directly in the coupling of light receptor rhodopsin 
to the GTP-binding protein transducin as reported by 
Hamm et al. [91. With respect to the partial sequence 
homology and comparable functional properties of the 
C-terminal regions of cys and crt, we investigated 
whether transducin-C-terminal peptide GTA 340-350 
causes comparable effects in Badrenergic signal 
transduction. As depicted in fig*1 , the peptide GTA 
340-350 was not able to compete for P-receptor-G, 
coupling. Furthermore, two other undecapeptides 
derived from the C-terminal region of pertussis toxin 
substrates @ii- and Lu,-subunits howed no inhibitory ef- 
fects (fig, I). These results taken together with the data 
of Hamm et al. 191 emphasize the importance of the 
carboxyl-terminal regions of G-protein a-subunits for 
the specific recognition of the appropriate target recep- 
tor. As additional control, the peptide GSA 192-206, 
which corresponds to the middle part of (Ye, did not ex- 
hibit any effects at comparable concentrations (fig. 1). 
To rule out the possible interference of the peptide 
GSA 379-394 in the interaction of G, to adenylate 
cyclase, receptor-independent cyclase activation was 
carried out. For that purpose the membranes were first 
preactivated with AIF;, theu allowed to interact with 
peptides before finally measuring cyclase activation 
(fig.2). The peptide GSA 379-394 inhibited slightly 
(20% at 100 PM) the fluoride-mediated 0, activation of 
adenylate cyclase. These results show clearly that the 
interruption of signal transduction by peptide GSA 
379-394 is caused mainly by inhibition of receptor-Gs 
coupling. 
As previously reported, the P-receptor peptide T 
138- 159 inhibited strongly the hormone-indu~d 
cyclase activation indicating that the second in- 
tracellular loop of turkey erythrocyte &receptor is 
directly involved in coupling to G, [I]. The 
simultaneous addition of the peptides GSA 379-394 
and T 138-159 to the membranes decreased the ICSO 
value to 3 pM indicating that the combined action of 
the peptides might be synergistic rather than additive 
(fig. 1). 
Using an approach similar to that described recently 
by Simonds et al. 1181, we studied the possible effects 
of antibodies raised against the (Ye peptides, GSA 
379-394 and GSA 192-206, on the transdu~ion of 
hormone signals in the adenylate cyclase system. Both 
antisera were characterized for their specificity in im- 
munoblots and were shown to be highly selective for ms 
(fig,3). The antibody AB-GSA 192-206 showed weak 
cross-reactivity with the ai-subunit. Although the pep- 
tide sequences were taken from the known sequences of 
mammalian cws-subunits, the anti-peptide antibodies 
recognized equally well the ays from turkey erythrocyte 
membranes. This is in accordance with the fact that 
both mammalian and avian G,-proteins are able to ac- 
tivate adenylate cyclase, as has already been shown us- 
ing purified com~nents of &adrenergic signal chain 
reconstituted in phospholipid vesicles [ 161, As depicted 
ut_.a 
8.1 1 ti IUR IRRR 
Peptfda QIH, 
Fig.2. Effects of synthetic peptides on G,-mediated cyclase activation 
in turkey erythrocyte membranes. Fluoride-activated membranes 
were incubated with peptides for 60 min at 4°C and the cyclase 
activation was carried out for 20 min at 32% as described in section 
2. The peptide GTA 340-350 (x) represents the C-terminus of 
transducin a, GGA 343-354 (A) represents the C-terminus of cue, 
GSA 192~206 (+) and GSA 379-394 (0) are derived from n;, and T 
138-159 represents the second intracellular loop of the 
&adrenoceptor. 
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Fig.3. Analysis of specificity of anti-as-peptide antisera to the 
partially purified G./Gi preparation by immunoblotting. (A) SDS- 
PAGE and silver staining of G,/Gi fraction used for 
immunoblotting. The amounts of as- and cyi-subunits were 
50-100 ng. (B) Immunoblotting of G,/Gi fraction with antiserum 
AB-GSA 379-394 (lane 1) and antiserum AB-GSA 192-206 (lane 4). 
The lanes 2 and 3 represent he addition of 10 nM and 1 pM of the 
peptide GSA 379-394 to the antiserum AB-GSA 379-394 prior to 
immunostaining. The lanes 5 and 6 show the addition of 10 nM and 
1 ,uM of the peptide GSA 192-206 to the antiserum AB-GSA 
192-206. 
in fig.3, the preincubation of the antibodies AB-GSA 
379-394 and AB-GSA 192-206 with their correspon- 
ding peptides prevented in concentration-dependent 
manner the specific recognition of a, in immunoblots. 
When we compared the capability of peptides or 
their corresponding antibodies to serve as functional 
probes, significant differences became apparent. In 
analogy to the peptide results (see fig.l), the antibody 
AB-GSA 379-394 did indeed strongly inhibit hormone- 
stimulated cyclase activation, with a half-maximal in- 
hibition at approximately 1: 200 dilution (fig.4). 
However, the antibody AB-GSA 192-206 still caused 
40% inhibition of initial activity at 1: 50 dilution, 
which points to a more global contribution of the 
recognition site to the total reactivity. The receptor- 
independent cyclase activation (fluoride activation, see 
fig.4) was also impaired to a considerable extent when 
the antibody AB-GSA 379-394 was used. The results 
from peptide competition appear much more selective, 
since the peptide GSA 379-394 attenuated exclusively 
the receptor-Gs coupling. Bearing this in mind, the par- 
tial inhibition of fluoride-stimulated cyclase activity by 
AB-GSA 379-394 and the corresponding effects 
reported by Simonds et al. [ 181 have to be interpreted 
cautiously. Our data from peptide competition make it 
clear that there is no direct involvement of the 
carboxyl-terminal part in coupling of cys to adenylate 
cyclase. There is an additional advantage in studies us- 
Prcimur Scru x 
IM-CSII 1%~216 4 
Antlserm Dilution Factor 
f Iso/TTPfi +,A; MF 0, A 1 
Fig.4. Inhibition of &adrenergic signal transduction in turkey 
erythrocyte membranes by antibodies raised against synthetic 
peptides derived from as-subunit. Membranes were preincubated 
with the antiserum AB-GSA 379-394 (0, t) or AB-GSA 192-206 
(A , A) overnight at 4°C. The receptor-induced cyclase activation 
(+ , A) was carried out with lo-’ M L-isoproterenol and 5 x lo-’ M 
GTPrS while the fluoride-mediated activation (0, A) was achieved 
with 10 mM NaF, 30,~M Ah% and 6 mM MgCl2 as described in 
section 2. 
ing site-specific peptide competition. Whereas peptides 
could be synthesized easily with a defined number of 
residues, heteroclonal antibodies generally represent an 
unknown mixture of composite sites. 
The methods used here provide the potential tools to 
search for other regions of G, interaction with the p- 
adrenoceptor. Thus, more specific synthetic peptides 
and the reconstituted system with purified components 
[16] should provide more information on structure- 
function relationships. Additionally, we expect to iden- 
tify more precisely the crucial amino acids of the C- 
terminal region of different a-subunits which seem to 
determine the receptor specificity for different G- 
proteins. The strategy of site-specific peptide competi- 
tion has proved to be superior to the anti-peptide an- 
tibody technique where non-functional effects like 
steric hindrance, loss of lateral and conformational 
mobility and precipitation of components can lead to 
ambiguities in the interpretation of the results. Lacking 
these disadvantages, the synthetic peptides represent a 
powerful tool for the identification of functional do- 
mains in protein-protein interactions. 
Acknowledgements: We are indebted to E.J.M. Helmreich for his in- 
terest and support of this work. The transducin cu-peptide GTA 
340-350 was kindly provided by K.P. Hofmann, Freiburg. We thank 
B. Fischer for expert technical assistance with peptide synthesis and 
antibody preparation. We acknowledge the donation of the Applied 
Biosystems Peptide Synthesizer by the Fonds der Chemischen In- 
dustrie and the Bundesministerium fiir Forschung und Technologie. 
This work was supported in part by the Deutsche Forschungsge- 
meinschaft, Grant Pa 92120 and SFB 176, Projekt Helmreich-Al. 
297 
Volume 261, number 2 FEBS LETTERS February 1990 
REFERENCES 
[l] Palm, D., Munch, G., Dees, C. and Hekman, M. (1989) FEBS 
Lett. 254, 89-93. 
[2] Freissmuth, M., Casey, P.J. and Gilman, A.G. (1989) FASEB 
J. 3, 2125-2131. 
[3] Bray, P., Carter, A., Simons, C., Guo, V., Puckett, C., 
Kamholz, J., Spiegel, A. and Nirenberg, M. (1986) Proc. Natl. 
Acad. Sci. USA 83, 8893-8897. 
[4] Hanski, E., Sternweis, P.C., Northup, J.K., Dromerick, A.W. 
and Gilman, A.G. (1981) J. Biol. Chem. 256, 12911-12919. 
[5] Mattera, R., Codina, J., Crozat, A., Kidd, V., Woo, S.L.C. 
and Birnbaumer, L. (1986) FEBS Lett. 206, 36-42. 
[6] Masters, S.B., Stroud, R.M. and Bourne, H.R. (1986) Protein 
Eng. 1, 47-54. 
[7] Rall, T. and Harris, B.A. (1987) FEBS Lett. 224, 365-371. 
[8] Sullivan, K.A., Miller, R.T., Maters, S.B., Beiderman, B., 
Heideman, W. and Bourne, H.R. (1987) Nature 330, 758-760. 
[9] Hamm, H.E., Deretic, D., Arendt, A., Hargrave, P.A., 
Koenig, B. and Hofmann, K.P. (1988) Science 241, 832-835. 
[lo] Cerione, R.A., Kroll, S., Rajaram, R., Unson, C., Goldsmith, 
P. and Spiegel, A.M. (1988) J. Biol. Chem. 263, 9345-9352. 
[ll] Green, N., Alexander, H., Olson, A., Alexander, S., Shinnick, 
T.M., Sutcliffe, J.G. and Larner, R.A. (1982) Cell 28, 
477-487. 
1121 Tamura, T., Bauer, H., Birr, C. and Pipkorn, R. (1983) Cell 
34, 587-596. 
[13] Van Regenmortel, M.H.V., Briand, J.P., Muller, S. and Plaue, 
S. (1988) Synthetic Polypeptides as Antigens, pp.145-157, 
Elsevier, Amsterdam. 
[14] Janssen Biotech, Belgium (1988) Product manual. 
1151 Puchwein, G., Pfeuffer, T. and Helmreich, E.J.M. (1974) J. 
Biol. Chem. 249, 3232-3240. 
[la] Feder, D., Im, M.-J., Klein, H.W., Hekman, M., Holzhofer, 
A., Dees, C., Levitzki, A., Helmreich, E. J.M. and Pfeuffer, T. 
(1986) EMBO J. 5, 1509-1514. 
[17] Salomon, Y., Londos, C. and Rodbell, M. (1974) Anal. 
Biochem. 58, 541-548. 
[18] Simonds, W.F., Goldsmith, P.K., Woodard, C.J., Unson, 
C.G. and Spiegel, A.M. (1989) FEBS Lett. 249, 189-194. 
[19] Lochrie, M.A. and Simon, M.I. (1988) Biochemistry 27, 
4957-4965, 
298 
